# DuPont account plan

> DuPont makes healthcare, water, construction and industrial materials: $6,849 million 2025 continuing net sales, about 15,000 employees.

## At a glance

DuPont de Nemours, Inc. (NYSE: DD), headquartered in Wilmington, Delaware, sells engineered materials and solutions to manufacturers and distributors in healthcare, water, construction and industrial markets, under brands such as Tyvek, Tychem, FilmTec, Amberlite, Styrofoam, Corian, Vespel and Molykote. It has subsidiaries in about 50 countries, manufacturing in about 20, and approximately 15,000 employees at December 31, 2025. Continuing net sales were $6,849 million in 2025 (+2%), with income from continuing operations of $98 million and a net loss of $738 million after an $836 million loss from discontinued operations. 2025 was the first year of the "New DuPont": the electronics business was spun off as Qnity Electronics on November 1, 2025, and the Aramids business was sold to Arclin (TJC) on April 1, 2026.

## Business units

- **Healthcare & Water Technologies** (about 47% of 2025 net sales ($3,233 million)): Packaging, parts and components for medical device and biopharma customers, and water filtration and purification for industrial, municipal, desalination and life sciences markets. 2025 sales rose 9% and Operating EBITDA 15% to $972 million; Q3 2026 sales were $865 million (+4%) with Operating EBITDA of $263 million (+7%).
- **Healthcare Technologies** (about 26% of 2025 net sales ($1,758 million)): Specialty medical-device components, Tyvek medical packaging and garments, and Tychem protective suits, including the Spectrum and Donatelle acquisitions. The CEO sized Tyvek in healthcare at "about $1 billion", split roughly between medical packaging and garments; Q3 2026 growth came from personal protection and medical packaging.
- **Water Technologies** (about 22% of 2025 net sales ($1,475 million)): Amberlite ion exchange resins, FilmTec reverse osmosis and nanofiltration elements, and Inge and Itegratec ultrafiltration modules. Semiconductor demand is about 20% of ion exchange and rose around 20% with AI data centres, while Middle East disruption pushed about $15 million of large projects into 2027.
- **Diversified Industrials** (about 53% of 2025 net sales ($3,616 million)): Engineered products for construction and industrial markets, including aerospace, automotive and electric vehicles. 2025 sales fell 3% and Operating EBITDA 5% to $800 million; Q3 2026 sales were $1,003 million (+4%) with Operating EBITDA of $242 million (+11%).
- **Industrial Technologies** (about 29% of 2025 net sales ($2,003 million)): Vespel parts, Molykote lubricants, Betaforce and Betaseal adhesives and Cyrel printing plates for automotive, aerospace, printing and packaging OEMs. Aerospace is about $300 million and grows double digits; EV battery sales rose about 60% in 2026.
- **Building Technologies** (about 24% of 2025 net sales ($1,613 million)): Tyvek house wrap, Styrofoam insulation and Corian solid surface for residential, non-residential and repair-and-remodel construction. Volumes declined in 2025 on weak construction markets; in Q3 2026 it grew mid-single digits organically on price and share gains with national and large regional builders.

## Strategic priorities

- **Above-market organic growth**: The 2026 priorities set at the September 2025 Investor Day are to "drive above-market organic growth, continue to build out a robust business system, deploy a balanced capital allocation model". 2026 guidance was raised to organic growth of approximately 4.5% and sales of about $7.19 billion.
- **Healthcare and water growth**: Growth is expected in medical packaging and medical devices, and in reverse osmosis and ion exchange for industrial and municipal water. The early 2027 view is mid-single-digit growth in healthcare and water excluding the Middle East.
- **Business system and productivity**: DuPont targets net productivity of 3% of COGS (a little over 2% in Q3 2026) and on-time-in-full of 95%, now in the low 80s. 80/20 was piloted on about $700 million of Diversified Industrials revenue and extended to Molykote.
- **Innovation mix toward growth**: DuPont launched more than 125 new products in 2025 with over $2 billion of new-product sales; the vitality index is in the mid-30% range, and the goal is to move from about 60% replace / 40% growth to 50/50. Gen 4 reverse osmosis from Edina is due in 2027.
- **AI across innovation, sales and service**: Agents in two businesses cut the front-end stage-gate step from about three months to about five days, AI-enabled sales plays lifted Tyvek garments by $5-6 million, and Copilot is available to every exempt employee. Sales pay moves to commission-based from January 1, 2027.

## Latest results

In Q3 2026 net sales were $1,868 million, up 4% (organic +5%), and income from continuing operations was $171 million against $102 million a year earlier. Operating EBITDA was $469 million, a 25.1% margin, and cost of sales fell to 64% of sales from 66% on manufacturing productivity. Nine-month sales were $5,368 million (+4%) and operating cash flow from continuing operations was $1,042 million, against $473 million. Full-year 2026 guidance was raised to sales of about $7.19 billion, operating EBITDA of $1.785 billion and adjusted EPS of $7.50 at the midpoint; Q4 is guided at sales of $1.825 billion.

## Investments and deals

- **Healthcare bolt-on acquisitions**: DuPont bought Spectrum Plastics (August 2023, about $1,781 million) and Donatelle Plastics (July 2024, $365 million); M&A remains aimed mainly at healthcare, with about $1.5 billion of "firepower" left.
- **Water capacity in China**: Sinochem (Ningbo) RO Memtech, a Chinese reverse osmosis maker, was acquired in October 2025 for $56 million to add RO membrane capacity.
- **Portfolio separations**: Qnity paid DuPont about $4.1 billion at the November 2025 spin, and the Aramids sale closed on April 1, 2026 for about $1.2 billion pre-tax cash, a $300 million note and a $325 million equity interest.
- **Share buybacks**: Under a $2 billion authorization: a $500 million ASR in Q4 2025, a $275 million ASR in Q2 2026, a $250 million ASR in Q3 2026, and a further $250 million planned for Q4 2026.
- **Capex and restructuring**: Capex was $333 million in 2025 with about $320 million expected for 2026. The 2026 DuPont Restructuring Program expects $100-150 million of charges and other cost savings through 2028.

## Challenges and risks

- **PFAS legacy liabilities**: The New Jersey settlement (first $71 million payment in September 2026) and the North Carolina settlement of September 9, 2026 add multi-year payments, with Qnity bearing 44% of these funding obligations.
- **Middle East disruption**: The conflict that began in February 2026 disrupts Water sales in the region; about $15 million of large projects with orders in hand were pushed into 2027.
- **Weak construction and auto markets**: About 40% of the portfolio (construction and automotive) is in markets declining low single digits, and Building Technologies volumes fell in 2025 on "ongoing weakness in construction markets".
- **Separation tax and trade risks**: DuPont could owe significant tax if the Qnity, N&B or Dow/Corteva separations fail to qualify as tax-free, and it is exposed to tariffs, export controls and raw-material and energy cost inflation.
- **Delivery performance gap**: On-time-in-full is in the low 80s against a 95% target measured to request date.

## What leadership says

> "we are not going to make a hasty decision and do a deal just to do a deal." — Lori Koch, Chief Executive Officer, DuPont Q3 2026 earnings call, November 3, 2026

> "While we have the orders in hand for our large water projects in the Middle East, given the continued disruptions, our guidance now assumes these projects will be pushed into 2027" — Lori Koch, Chief Executive Officer, DuPont Q3 2026 earnings call, November 3, 2026

> "our portfolio is not a chemical company portfolio" — Antonella Franzen, SVP and Chief Financial Officer, DuPont 4Q 2025 earnings call, February 10, 2026


## Where a supplier can help

- **Productivity and delivery tools**: Tied to the business-system priority and the delivery gap: suppliers of lean, maintenance, planning or supply-chain tools could help lift on-time-in-full from the low 80s toward 95% and net productivity toward 3% of COGS.
- **Commercial excellence and sales enablement**: Tied to the AI priority and the move to commission-based sales pay from January 2027: sales-performance, incentive-compensation and AI sales-play tools fit a sales force being re-tooled.
- **Medical-device contract manufacturing inputs**: Tied to healthcare growth and bolt-on M&A: suppliers of components, equipment and quality systems for medical packaging and device manufacturing serve the fastest-growing segment.
- **Water capacity and semiconductor demand**: Tied to water growth and the China RO acquisition: equipment, process and logistics suppliers can support membrane capacity and ion exchange demand from AI data centres.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [DuPont de Nemours, Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1666700/000166670026000013/dd-20251231.htm)

Annual report · 2026-02-17

- DuPont de Nemours describes itself as "a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets", with subsidiaries in about 50 countries, manufacturing in about 20 and approximately 15,000 employees at December 31, 2025 (about 1,700 in the Aramids business then being sold).
- 2025 is the first 10-K of the "New DuPont": the electronics business was spun off as Qnity Electronics, Inc. on November 1, 2025, and the Aramids business was agreed for sale to Arclin (TJC) for about $1.2 billion pre-tax cash plus a $300 million note and a $325 million equity stake; both are discontinued operations.
- Continuing net sales were $6,849 million in 2025 (+2%; volume +3%, local price and mix -1%). Income from continuing operations was $98 million; net loss was $738 million after an $836 million loss from discontinued operations, including a $768 million Aramids goodwill impairment.
- Two new reportable segments since Q4 2025: Healthcare & Water Technologies ($3,233 million sales, +9%; Operating EBITDA $972 million, +15%) and Diversified Industrials ($3,616 million, -3%; Operating EBITDA $800 million, -5%).
- Four businesses: Industrial Technologies ($2,003 million), Healthcare Technologies ($1,758 million), Building Technologies ($1,613 million) and Water Technologies ($1,475 million). Brands include Tyvek, Tychem, FilmTec, Amberlite, Styrofoam, Corian, Vespel, Molykote, Betaforce/Betaseal and Cyrel.
- Capital structure was reset around the spin: Qnity paid DuPont about $4.1 billion, total debt fell from $7.2 billion to $3.2 billion, and a $2 billion buyback authorization was approved (a $500 million ASR was run in Q4 2025). 2025 capex was $333 million; about $320 million is expected for 2026.
- 2026 outlook: continued growth in Healthcare (medical packaging, medical devices) and Water (reverse osmosis, ion exchange), Building Technologies about flat, and low-single-digit growth in Industrial Technologies led by aerospace.
- Main risks are the tax treatment of the Qnity, N&B and Dow/Corteva separations, PFAS liabilities shared under the 2021 MOU with Corteva and Chemours (44% now allocated to Qnity), the New Jersey settlement, trade and tariff disputes, and raw-material and energy costs.
- Lori D. Koch is CEO, Edward D. Breen is Chairman and Antonella B. Franzen is SVP and CFO.

### [DuPont de Nemours, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1666700/000166670026000060/dd-20260930.htm)

Interim report · 2026-11-03

- Q3 2026 net sales were $1,868 million, up 4% (organic +5%, currency -1%). Nine-month sales were $5,368 million, up 4%. Income from continuing operations was $171 million in Q3 and $512 million over nine months.
- Healthcare & Water Technologies: Q3 sales $865 million (+4%, organic +4%), Operating EBITDA $263 million (+7%), driven by personal protection, medical packaging, and industrial water and semiconductor markets, partly offset by continued disruption in the Middle East.
- Diversified Industrials: Q3 sales $1,003 million (+4%, organic +5%), Operating EBITDA $242 million (+11%), on aerospace, EV battery applications, and Building Technologies growth in North America and Asia Pacific.
- The Aramids sale to Arclin (TJC) closed on April 1, 2026, for about $1.2 billion pre-tax cash, a $300 million note and a $325 million equity interest. A 1-for-3 reverse stock split took effect on June 24, 2026.
- Cash was $1,652 million and debt $3,094 million at September 30, 2026. Nine-month operating cash flow from continuing operations was $1,042 million, against $473 million a year earlier.
- Buybacks under the $2 billion authorization: a $275 million ASR in Q2, a $250 million ASR in Q3, a $100 million open-market programme, and a further $250 million planned for Q4 2026. The quarterly dividend is $0.60 per share.
- PFAS legacy: the New Jersey settlement was finalised on August 7, 2026 (first $71 million payment), and a North Carolina settlement was signed on September 9, 2026. Qnity bears 44% of these funding obligations.
- A 2026 DuPont Restructuring Program expects $100-150 million of charges and other cost savings through 2028. The 10-Q flags the February 2026 Middle East conflict and the Supreme Court's invalidation of IEEPA tariffs.

### [DuPont Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/11/03/dupont-dd-q3-2026-earnings-call-transcript/)

Executive talk · Lori Koch, Chief Executive Officer · 2026-11-03

- CEO Lori Koch and CFO Antonella Franzen reported Q3 2026 organic growth of 5%, 90 basis points of margin expansion and 31% adjusted EPS growth. Full-year 2026 guidance was raised again: organic growth about 4.5%, sales about $7.19 billion, operating EBITDA $1.785 billion, and adjusted EPS of $7.50 at the midpoint.
- Large Middle East water projects (about $15 million) are pushed into 2027 despite orders in hand. Excluding the Middle East, Water grows mid-single digits; ion exchange for semiconductors was up about 20% on the AI data-centre build-out.
- Growth pockets: aerospace (about $300 million, about 3% of revenue, low double-digit growth via Vespel and Tedlar), EV battery sales (up about 60% this year), Tyvek medical packaging and garments, and share gains in Tyvek house wrap.
- Operating model: net productivity of a little over 2% (target 3% of COGS), on-time-in-full in the low 80s against a 95% target, 80/20 rolled out in Diversified Industrials (now including Molykote), R&D at about 2.5% of sales sitting within the businesses, and a vitality index in the mid-30% range.
- AI is used across innovation (front-end stage gates cut from about three months to about five days in two businesses), commercial sales plays ($5-6 million of lift in Tyvek garments) and customer service. Copilot is available to every exempt employee.
- Sales force pay moves to commission-based from January 2027.
- Capital: net debt/EBITDA of 1.1x, buybacks of about 7% of shares announced since the spin, and about $1.5 billion of "firepower" left for M&A. Koch: "we are not going to make a hasty decision and do a deal just to do a deal."
- 2027 early view: end markets similar to 2026, with a slight auto improvement, mid-single-digit healthcare and water (ex Middle East), and continued margin expansion from productivity.

### [DuPont 4Q 2025 earnings call transcript](https://s23.q4cdn.com/116192123/files/doc_events/2026/Feb/10/DuPont-4Q-2025-Earnings-Call-Transcript.pdf)

Executive talk · Lori Koch, Chief Executive Officer · 2026-02-10

- On the first full-year call after the Qnity spin, CEO Lori Koch reported 2025 organic growth of 2%, operating EBITDA up 6%, 100 basis points of margin expansion, and adjusted EPS of $1.68 (up 16%).
- 2026 priorities, as set at the September 2025 Investor Day: "drive above-market organic growth, continue to build out a robust business system, deploy a balanced capital allocation model".
- 2026 guidance (pre-reverse-split): organic growth of about 3%, net sales of about $7.1 billion, operating EBITDA of about $1.74 billion, 60-80 basis points of margin expansion, adjusted EPS of $2.25-$2.30, and free cash flow conversion above 90%.
- Innovation: more than 125 new products in 2025, over $2 billion of new-product sales, a vitality index of about 30%, and about 145 basis points of margin lift from products launched in the past five years. Upcoming: enhanced Tyvek garments and Gen 4 reverse osmosis from Edina for 2027.
- Segments for 2026: Healthcare & Water mid-single-digit organic growth, Diversified Industrials low-single-digit. Shelter (Building) is about flat, aerospace orders are up low double digits, and China water starts slowly.
- Capital: Aramids proceeds of about $1.1 billion after tax, half already used by the $500 million ASR. M&A is aimed mainly at healthcare (med-device bolt-ons like Spectrum and Donatelle), at deal IRRs above the cost of capital by year five. About $1 billion of cash is held.
- Franzen: "our portfolio is not a chemical company portfolio"; DuPont is pushing to change its GICS classification.

## Questions about DuPont

### What does DuPont do?

DuPont makes engineered materials and solutions for healthcare, water, construction and industrial markets, including Tyvek, FilmTec, Amberlite, Styrofoam, Corian, Vespel and Molykote. It reports two segments: Healthcare & Water Technologies and Diversified Industrials.

### What is DuPont's revenue?

Continuing net sales were $6,849 million in 2025, up 2%. For 2026 DuPont guides to sales of about $7.19 billion.

### How many employees does DuPont have?

Approximately 15,000 at December 31, 2025, of whom about 1,700 were in the Aramids business that was later sold.

### Who leads DuPont?

Lori D. Koch is CEO, Edward D. Breen is Chairman and Antonella B. Franzen is SVP and CFO.

### What is DuPont's strategy?

After spinning off Qnity and selling Aramids, DuPont focuses on above-market organic growth in healthcare and water, a business system built on productivity and 80/20, and balanced capital allocation between buybacks and healthcare bolt-on M&A.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
